18F-FES PET/CT's Additional Clinical Value in ER+ BC

18F-FES PET/CT Influences the Staging and Management of Newly Diagnosed Oestrogen Receptor-Positive Breast Cancer Patients: A Retrospective Comparative Study With 18F-FDG PET/CT

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04006626

Enrollment

Registered

2019-07-05

Start date

2019-02-15

Completion date

2019-06-20

Last updated

2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

To figure out whethetr 18F-FES PET/CT could influence the staging and management of newly diagnosed Oestrogen Receptor-positive Breast Cancer Patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients with newly diagnosed immunohistochemical confirmed oestrogen receptor (ER)-positive breast cancer * Patients underwent both 18F-FES PET/CT and 18F-FDG PET/CT in Fudan University Shanghai Cancer Center within 1 week after diagnosis * Patients with available medical history

Exclusion criteria

* Patients with incomplete medical history

Design outcomes

Primary

Measure	Time frame	Description
Staging of breast cancer	6 weeks	Deliver questionnaire to phycians to investigate the staging of BC according to AJCC 8 (TNM staging).

Countries

China

Outcome results